Business Context and Reporting Period
This Form 8-K was filed by Oculus Innovative Sciences, Inc. on April 2, 2014. The report discloses the entry into a material definitive agreement regarding a new equity financing mechanism. Note: The request metadata references "Sonoma Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as Oculus Innovative Sciences, Inc.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the potential capital raise:
- Maximum Offering Size: Up to $9,159,000 in aggregate offering price.
- Commission Rate: 3.0% of gross proceeds paid to the sales agent.
- Reimbursable Expenses: Up to $25,000 for expenses incurred by the sales agent.
Material Changes
The material change reported is the execution of an At-the-Market Issuance Sales Agreement with MLV & Co. LLC. This agreement authorizes the company to sell shares of its common stock through MLV acting as a sales agent. The company is not obligated to sell any shares, and no assurance is given regarding the price, amount, or timing of any future sales.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the company's intentions and the planned spin-off. Management notes that actual outcomes may differ materially due to risks and uncertainties. Specific risks include the inability to sell shares under the agreement or unfavorable market conditions affecting the price of shares sold. The agreement will terminate upon the sale of all authorized shares or as otherwise provided in the contract.
Investor Verification Checklist
- Verify the exact number of shares authorized for sale under the $9,159,000 cap based on the current market price.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific termination clauses and sales parameters.
- Confirm the company's current cash position and liquidity needs to assess the urgency of utilizing this facility.
- Check subsequent filings to determine if any shares have actually been sold under this agreement.